(AOF) – Quantum Genomics has announced the signing of an exclusive license agreement with Teva Israel Ltd. – subsidiary of Teva Pharmaceutical Industries Ltd – to market firibastat in Israel. Teva will receive exclusive marketing rights for its historic market in the resistant and difficult-to-treat hypertension indication. The French biopharmaceutical company will receive payments of up to $ 11 million as well as royalties ranging from 25% up to 30% on future sales of firibastat.
“Today we are proud to enter into a partnership with one of the greatest successes in the pharmaceutical industry, which will undoubtedly make firibastat a commercial success in its historical market. We are already discussing the extension of this exclusive license to new territories where Teva is established “, declared Jean-Philippe Milon, CEO of Quantum Genomics.
©
AOF
Legal disclaimer
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights owned by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial or non-commercial exploitation, creation of hypertext link or reuse in any way whatsoever of this information is subject to the prior written agreement of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from sources it considers the most reliable. However, subject to gross negligence, OPTION FINANCES SAS and its contributors in no way guarantee the absence of errors and defects, even hidden, nor the exhaustiveness or lack of conformity for any use whatsoever of these data and of OPTION FINANCE. SAS or one of its contributors, and cannot be held responsible for delays or interruptions that could affect access to them. The user of the OPTION FINANCE SAS service will use AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember about financial markets.
